Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00226746
Status:
WITHDRAWN
Last Update Posted:
2020-09-18
First Post:
2005-09-23
Brief Title:
Efficacy Study of Gemcitabine Paclitaxel and Irradiation in the Treatment of Pancreatic Cancer
Sponsor:
New York Presbyterian Brooklyn Methodist Hospital
Organization:
New York Presbyterian Brooklyn Methodist Hospital
Study Overview
Official Title:
A Multicenter Phase II Trial of Weekly Gemcitabine Paclitaxel and Hyperfractionated External Irradiation 6380 GY for Locally Advanced Pancreatic Cancer
Status:
WITHDRAWN
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out what effects good and bad the chemotherapy drugs gemcitabine Gemzar and paclitaxel Taxol have in combination with twice daily radiation treatment on locally advanced pancreatic cancer
Detailed Description:
Based on our previous experience with the use of a weekly paclitaxel dose of 60 mgm2 and hyperfractionated radiation therapy 638 Gy we are conducting this study incorporating the use of Gemcitabine at a dose level of 75 mgm2week in addition to our prior protocol
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None